Additional benefit may be gained with use of immune modulating adjuvants such as anti-PDL-1, anti-CTLA-4, GM-CSF, or IL-2 to overcome tolerance and optimize anti-tumor immunity. This evidence concerns the gene CSF2 and neoplasm.